Abacus Medicine
Abacus Medicine, a leading player in the pharmaceutical industry, is headquartered in Denmark (DK) and operates extensively across Europe. Founded in 2004, the company has established itself as a key provider of parallel-imported medicines, ensuring access to high-quality pharmaceuticals at competitive prices. Abacus Medicine's core services include sourcing, distributing, and supplying a wide range of prescription medications, with a focus on efficiency and compliance with regulatory standards. The company is renowned for its commitment to quality assurance and has achieved significant milestones, including partnerships with major healthcare providers. With a strong market position, Abacus Medicine continues to innovate in the pharmaceutical supply chain, making it a trusted name in the industry. Its unique approach to parallel imports not only enhances accessibility but also contributes to cost savings for healthcare systems across its operational regions.
DitchCarbon Score
How does Abacus Medicine's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Abacus Medicine's score of 22 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Abacus Medicine's reported carbon emissions
In 2023, Abacus Medicine reported total carbon emissions of approximately 859,500 kg CO2e, comprising about 216,900 kg CO2e from Scope 1 and about 642,600 kg CO2e from Scope 2 emissions. This marks a slight increase in Scope 1 emissions compared to 2022, where they were about 213,700 kg CO2e, while Scope 2 emissions also saw a rise from approximately 601,300 kg CO2e. Over the past five years, Abacus Medicine's emissions have fluctuated significantly. In 2019, the company recorded about 109,400 kg CO2e in Scope 1 emissions, which increased to about 239,000 kg CO2e in 2021. The total emissions for 2021 were approximately 1,200,000 kg CO2e when combining both Scope 1 and Scope 2 emissions. Despite these figures, there are currently no publicly disclosed reduction targets or climate pledges from Abacus Medicine, indicating a potential area for improvement in their climate commitments. The company operates within a global context where many organisations are increasingly setting ambitious targets to reduce their carbon footprints, aligning with industry standards for sustainability and climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 62,600 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | - | - | - | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Abacus Medicine is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
